Homeopathy and hetero-isotherapy, an interesting response to the side effects of targeted therapies in oncology

In 2015, one in four anti-cancer drugs is a targeted therapy. These innovative molecules, bringing hope and therapeutic progress, also bring new side effects, sometimes difficult to relieve with conventional therapies. When they occur, the quality of life is greatly altered, the dosage must be reduced and stopping treatment is sometimes necessary, causing a significant loss of opportunity for the patient. Faced by these recurring problems, the use of classical homeopathy and homeopathic dilution of targeted therapy in 7c (1 × 10−14), also called hetero-isotherapy, when available and necessary, is an appropriate response to improve tolerance to targeted therapies. With nearly 500 targeted therapies accompanied in this way, I have seen a significant decrease in side effects, allergic risk and late sequelae. Improved tolerance of targeted therapy and improved quality of life resulted in improved adherence to and, most often, maintenance of the initial posology. No disturbance of treatment activity was observed. The absence of toxicity and of drug interaction make homeopathy and hetero-isotherapeutics a supportive treatment of choice for the adverse effects of targeted therapies. This preliminary work should encourage carrying out randomised clinical studies.